Last reviewed · How we verify
Xenon Xe 129 Hyperpolarized MRI Ventilation Imaging for the Evaluation of Treatment Response Comparing Three Different Bronchodilator Aerosol Delivery Methods in Patients With COPD: A Pilot Study
The goal of this clinical trial is to compare responses to bronchodilator treatment delivered by three different aerosol delivery methods in patients with chronic obstructive pulmonary disease (COPD). The main question it aims to answer is whether there are differences in lung ventilation following treatment with each of the three methods as measured using hyperpolarized Xe 129 with MRI. Participants will: Receive a standard dose of albuterol delivered using each of 3 aerosol delivery devices. In total, participants will receive three treatments separated by at least 1 week each. Following each treatment, participants will have inhale an MRI contrast agent called hyperpolarized Xe 129 and will have images of their lungs taken with an MRI. Researchers will compare the different lung images taken after each treatment to see if there are differences in the distribution of air in the lungs (known as ventilation).
Details
| Lead sponsor | Polarean, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 6 |
| Start date | 2024-02 |
| Completion | 2024-04 |
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
- Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution
- Vibrating Mesh Nebulizer
- Metered Dose Inhaler
- Jet Nebulizer
Primary outcomes
- Ventilation Defect Percent — measured immediately postdose
A measure of the percentage of lung area with low ventilation measured using hyperpolarized Xe 129 MRI
Countries
United States